ARCHIVES

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 7 | July 27, 2012

Download PDF Visit The Full Archive

Related Articles

Ruffin Sworn In As Director, NIH Minority Health Center.

January 12, 2001

In Congress: Tamoxifen Results Well Communicated, Understood, NCI Says

May 1, 1998

NCCS Networker Volume 8 Issue 3, Fall 1994

September 12, 1994

In Brief: fraud By Trainee Leads Collins To Retract Five Paper; Weinstein Retires At Columbia

November 1, 1996

Construction Not Dead After All; DCPC Board Okays Architect/ Engineering Support Contract

February 13, 1987

NCI Cancer Prevention Fellowship Program

April 28, 2000